{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:46:24Z","timestamp":1794113184074,"version":"4.8.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Heparins and vitamin K antagonists are the mainstay of treatment of splanchnic vein thrombosis (SVT). Rivaroxaban is a potential alternative, but data to support its use are limited. We aimed to evaluate the safety and efficacy of rivaroxaban for the treatment of acute SVT. In an international, single-arm clinical trial, adult patients with a first episode of noncirrhotic, symptomatic, objectively diagnosed SVT received rivaroxaban 15 mg twice daily for 3 weeks, followed by 20 mg daily for an intended duration of 3 months. Patients with Budd-Chiari syndrome and those receiving full-dose anticoagulation for &amp;gt;7\u00a0days prior to enrollment were excluded. Primary outcome was major bleeding; secondary outcomes included death, recurrent SVT, and complete vein recanalization within 3 months. Patients were followed for a total of 6 months. A total of 103 patients were enrolled; 100 were eligible for the analysis. Mean age was 54.4 years; 64% were men. SVT risk factors included abdominal inflammation\/infection (28%), solid cancer (9%), myeloproliferative neoplasms (9%), and hormonal therapy (9%); 43% of cases were unprovoked. JAK2 V617F mutation was detected in 26% of 50 tested patients. At 3 months, 2 patients (2.1%; 95% confidence interval, 0.6-7.2) had major bleeding events (both gastrointestinal). One (1.0%) patient died due to a non\u2013SVT-related cause, 2 had recurrent SVT (2.1%). Complete recanalization was documented in 47.3% of patients. One additional major bleeding event and 1 recurrent SVT occurred at 6 months. Rivaroxaban appears as a potential alternative to standard anticoagulation for the treatment of SVT in non-cirrhotic patients. This trial was registered at www.clinicaltrials.gov as #NCT02627053 and at eudract.ema.europa.eu as #2014-005162-29-36.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007397","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T16:52:22Z","timestamp":1650387142000},"page":"3569-3578","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":63,"title":["Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-8879","authenticated-orcid":false,"given":"Walter","family":"Ageno","sequence":"first","affiliation":[{"name":"1Department of Medicine and Surgery, University of Insubria and Ospedale di Circolo Fondazione Macchi, Varese, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Beyer Westendorf","sequence":"additional","affiliation":[{"name":"2Dresden University Hospital, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Contino","sequence":"additional","affiliation":[{"name":"3Azienda Ospedaliera SS. Antonio e Biagio, Alessandria, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Bucherini","sequence":"additional","affiliation":[{"name":"4Ospedale di Faenza, AUSL Romagna, Ravenna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Sartori","sequence":"additional","affiliation":[{"name":"5Clinical Medicine, Azienda Ospedaliera Universitaria di Padova, Padova, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Senzolo","sequence":"additional","affiliation":[{"name":"6Multivisceral Transplant Unit-Gastroenterology, Azienda Ospedaliera Universitaria di Padova, Padova, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-9783","authenticated-orcid":false,"given":"Elvira","family":"Grandone","sequence":"additional","affiliation":[{"name":"7Thrombosis and Haemostasis Unit, Fondazione IRCCS \u201cCasa Sollievo della Sofferenza\u201d, S. Giovanni Rotondo, Italy;"},{"name":"8Obstetrics and Gynecology Department, University of Foggia, Foggia, Italy;"},{"name":"9Obstetrics and Gynecology Department, The First I.M. Sechenov Moscow State Medical University, Moscow, Russia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5081-8201","authenticated-orcid":false,"given":"Rita","family":"Santoro","sequence":"additional","affiliation":[{"name":"10Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8296-2972","authenticated-orcid":false,"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[{"name":"11Ottawa Hospital Research Institute, Department of Medicine, University of Ottawa, Ottawa, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Delluc","sequence":"additional","affiliation":[{"name":"11Ottawa Hospital Research Institute, Department of Medicine, University of Ottawa, Ottawa, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-5827","authenticated-orcid":false,"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[{"name":"12Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0991-2615","authenticated-orcid":false,"given":"Fulvio","family":"Pomero","sequence":"additional","affiliation":[{"name":"13Ospedale Michele and Pietro Ferrero, Verduno, Cuneo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Paolo","family":"Donadini","sequence":"additional","affiliation":[{"name":"1Department of Medicine and Surgery, University of Insubria and Ospedale di Circolo Fondazione Macchi, Varese, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0119-5204","authenticated-orcid":false,"given":"Alberto","family":"Tosetto","sequence":"additional","affiliation":[{"name":"14Hematology Department, S.\u00a0Bortolo Hospital, Vicenza, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Becattini","sequence":"additional","affiliation":[{"name":"15University of Perugia, Perugia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Martinelli","sequence":"additional","affiliation":[{"name":"16IRCCS Fondazione Ca\u2019 Granda Ospedale Maggiore Policlinico, Milano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Nardo","sequence":"additional","affiliation":[{"name":"17Ospedale di Busto Arsizio, Busto Arsizio, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bertoletti","sequence":"additional","affiliation":[{"name":"18CHU de St-Etienne, Service de M\u00e9decine Vasculaire et Th\u00e9rapeutique; INSERM, UMR1059, Universit\u00e9 Jean-Monnet, INSERM, CIC-1408, CHU de Saint-Etienne; INNOVTE, CHU de Saint-Etienne, Saint-\u00c9tienne, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Di Nisio","sequence":"additional","affiliation":[{"name":"19University \u201cG. d\u2019Annunzio\u201d of Chieti-Pescara, Chieti, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6869-8431","authenticated-orcid":false,"given":"Alejandro","family":"Lazo-Langner","sequence":"additional","affiliation":[{"name":"20Western University, London, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Schenone","sequence":"additional","affiliation":[{"name":"21Ospedale Galliera, Genoa, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8922-8823","authenticated-orcid":false,"given":"Nicoletta","family":"Riva","sequence":"additional","affiliation":[{"name":"22Faculty of Medicine and Surgery, University of Malta, Msida, Malta"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"issue":"4","key":"2022061715231719100_B1","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1160\/TH16-10-0781","article-title":"Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari syndrome","volume":"117","author":"Ageno","year":"2017","journal-title":"Thromb Haemost."},{"key":"2022061715231719100_B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2016.02.024","article-title":"Survival after splanchnic vein thrombosis: a 20-year nationwide cohort study","volume":"141","author":"S\u00f8gaard","year":"2016","journal-title":"Thromb Res."},{"issue":"9","key":"2022061715231719100_B3","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.2020006827","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis","volume":"137","author":"Valeriani","year":"2021","journal-title":"Blood."},{"key":"2022061715231719100_B4","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"issue":"1","key":"2022061715231719100_B5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.14309\/ajg.0000000000000486","article-title":"ACG clinical guideline: disorders of the hepatic and mesenteric circulation","volume":"115","author":"Simonetto","year":"2020","journal-title":"Am J Gastroenterol."},{"issue":"7","key":"2022061715231719100_B6","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jth.14836","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation","volume":"18","author":"Di Nisio","year":"2020","journal-title":"J Thromb Haemost."},{"issue":"4","key":"2022061715231719100_B7","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost."},{"issue":"11","key":"2022061715231719100_B8","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost."},{"key":"2022061715231719100_B9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.vph.2018.05.002","article-title":"Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis","volume":"113","author":"Hanafy","year":"2019","journal-title":"Vascul Pharmacol."},{"issue":"2","key":"2022061715231719100_B10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/rth2.12480","article-title":"Direct oral anticoagulants for unusual-site venous thromboembolism","volume":"5","author":"Riva","year":"2021","journal-title":"Res Pract Thromb Haemost."},{"issue":"1","key":"2022061715231719100_B11","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology."},{"issue":"9","key":"2022061715231719100_B12","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamainternmed.2015.3184","article-title":"Long-term clinical outcomes of splanchnic vein thrombosis. Results of an international registry","volume":"175","author":"Ageno","year":"2015","journal-title":"JAMA Intern Med."},{"issue":"10","key":"2022061715231719100_B13","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/S2352-3026(18)30133-9","article-title":"Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort study","volume":"5","author":"S\u00f8gaard","year":"2018","journal-title":"Lancet Haematol."},{"issue":"7","key":"2022061715231719100_B14","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1055\/s-0040-1722192","article-title":"Anticoagulant treatment for splanchnic vein thrombosis in liver cirrhosis: a systematic review and meta-analysis","volume":"121","author":"Valeriani","year":"2021","journal-title":"Thromb Haemost."},{"issue":"6","key":"2022061715231719100_B15","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/jth.12930","article-title":"Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study","volume":"13","author":"Riva","year":"2015","journal-title":"J Thromb Haemost."},{"issue":"4","key":"2022061715231719100_B16","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/bloodadvances.2019001310","article-title":"The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis","volume":"4","author":"Naymagon","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"2022061715231719100_B17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mayocp.2017.10.007","article-title":"Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location","volume":"93","author":"Janczak","year":"2018","journal-title":"Mayo Clin Proc."},{"issue":"3","key":"2022061715231719100_B18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/0268355518779517","article-title":"Evaluation of direct oral anticoagulants and vitamin K antagonists in mesenteric venous thrombosis","volume":"34","author":"Salim","year":"2019","journal-title":"Phlebology."},{"issue":"7","key":"2022061715231719100_B19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med."},{"issue":"20","key":"2022061715231719100_B20","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022061715231719100_B21","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"issue":"5","key":"2022061715231719100_B22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022061715231719100_B23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J."},{"issue":"1","key":"2022061715231719100_B24","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(15)00257-4","article-title":"Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study","volume":"3","author":"Ageno","year":"2016","journal-title":"Lancet Haematol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/12\/3569\/1902289\/advancesadv2022007397.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/12\/3569\/1902289\/advancesadv2022007397.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T15:24:04Z","timestamp":1655479444000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/12\/3569\/484971\/Rivaroxaban-for-the-treatment-of-noncirrhotic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,6,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007397","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]}}}